Half Year 2025 Aiforia Technologies Oyj Earnings Call Transcript
Key Points
- Aiforia Technologies PLC (OHEL:AIFORIA) achieved a 58% growth in their order book compared to the previous year.
- The company secured significant clinical agreements, including deals with major institutions like the NHS and Memorial Group in Turkey.
- Aiforia Technologies PLC has built the largest portfolio of CE-IVD solutions in the market, enhancing their competitive edge.
- The company has successfully integrated with multiple image management and scanner vendors, strengthening their market position.
- Aiforia Technologies PLC reported a 60% growth in their clinical business, indicating strong progress in their strategic focus area.
- Overall revenue growth was only 2%, indicating stagnation in some areas of the business.
- The company reported a negative EBITDA of EUR 3 million, despite improvements from the previous year.
- There was a slight decrease in the order book from the end of last year, raising concerns about future revenue recognition.
- Aiforia Technologies PLC experienced increased operating costs due to investments in computer power and sample purchases.
- The company is still in a growth phase, requiring continued investment, which may impact short-term profitability.
Yes. Good afternoon. My name is Jukka Tapaninen, Aiforia CEO, and welcome, everybody, to first half earnings announcement today. So I'm going to give some highlights of what happened in the first six months. And Veli-Matti, our CFO, will go through the numbers, and then I will highlight a little bit our strategy going forward.
But let's get started. The first half of the year, so it was in many ways, I think, really, really good. So we have some new closings on the customer side, and I will cover this in a later part of the presentation. So our order book grew 58% comparing to last year situation. So -- and -- on the revenue side, we were flat, but there are some good reasons why that happened. But all in all, on the sales side, we got a good success, and we were progressing as planned on getting those kind of the first clinical customers on -- so that we can use as a reference, and we can scale with those customers and then as a showcase for the others. So significant amount of those clinical agreements done.
But what
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
